Influence of CYP2D6, CYP3A5, ABCB1, APOE polymorphisms and nongenetic factors on donepezil treatment in patients with Alzheimer’s disease and vascular dementia

References

• Masters CL, Bateman R, Blennow K, Rowe CC, Sperling RA, Cummings JL. Alzheimer’s disease. Nat Rev Dis Primers. 2015;1:15056. doi:10.1038/nrdp.2015.5627188934
   PubMed Web of Science ®Google Scholar
• Ferri CP, Prince M, Brayne C, et al. Global prevalence of dementia: a Delphi consensus study. Lancet. 2005;366(9503):2112–2117. doi:10.1016/S0140-6736(05)67889-016360788
   PubMed Web of Science ®Google Scholar
• Birks JS, Harvey RJ. Donepezil for dementia due to Alzheimer’s disease. Cochrane Database Syst Rev. 2018;6:1–2.
   Google Scholar
• Malouf R, Birks J. Donepezil for vascular cognitive impairment. Cochrane Database Syst Rev. 2004;1:1–2.
   Google Scholar
• Noetzli M, Eap CB. Pharmacodynamic, pharmacokinetic and pharmacogenetic aspects of drugs used in the treatment of Alzheimer’s disease. Clin Pharmacokinet. 2013;52(4):225–241. doi:10.1007/s40262-013-0038-923408070
   PubMed Web of Science ®Google Scholar
• Cacabelos R. Donepezil in Alzheimer’s disease: from conventional trials to pharmacogenetics. Neuropsychiatr Dis Treat. 2007;3(3):303–333.19300564
   PubMedGoogle Scholar
• Lu J, Wan L, Zhong Y, et al. Stereoselective metabolism of donepezil and steady-state plasma concentrations of S-donepezil based on CYP2D6 polymorphisms in the therapeutic responses of Han Chinese patients with Alzheimer’s disease. J Pharmacol Sci. 2015;129(3):188–195. doi:10.1016/j.jphs.2015.10.01026603528
   PubMed Web of Science ®Google Scholar
• Saumier D, Murtha S, Bergman H, Phillips N, Whitehead V, Chertkow H. Cognitive predictors of donepezil therapy response in Alzheimer disease. Dement Geriatr Cogn Disord. 2007;24(1):28–35. doi:10.1159/00010256917495473
   PubMed Web of Science ®Google Scholar
• Cacabelos R, Torrellas C, Carrera I. Opportunities in pharmacogenomics for the treatment of Alzheimer’s disease. Future Neurol. 2015;10(3):229–252. doi:10.2217/fnl.15.12
   Web of Science ®Google Scholar
• Jann MW, Shirley KL, Small GW. Clinical pharmacokinetics and pharmacodynamics of cholinesterase inhibitors. Clin Pharmacokinet. 2002;41(10):719–739. doi:10.2165/00003088-200241100-0000312162759
   PubMed Web of Science ®Google Scholar
• Kim HG, Moon M, Choi JG, et al. Donepezil inhibits the amyloid-beta oligomer-induced microglial activation in vitro and in vivo. Neurotoxicology. 2014;40:23–32. doi:10.1016/j.neuro.2013.10.00424189446
   PubMed Web of Science ®Google Scholar
• Magliulo L, Dahl ML, Lombardi G, et al. Do CYP3A and ABCB1 genotypes influence the plasma concentration and clinical outcome of donepezil treatment? Eur J Clin Pharmacol. 2011;67(1):47–54. doi:10.1007/s00228-010-0883-520931330
   PubMed Web of Science ®Google Scholar
• Zhou SF. Polymorphism of human cytochrome P450 2D6 and its clinical significance: part I. Clin Pharmacokinet. 2009;48(11):689–723. doi:10.2165/11318030-000000000-0000019817501
   PubMed Web of Science ®Google Scholar
• Pilotto A, Franceschi M, D’Onofrio G, et al. Effect of a CYP2D6 polymorphism on the efficacy of donepezil in patients with Alzheimer disease. Neurology. 2009;73(10):761–767. doi:10.1212/WNL.0b013e3181b6bbe319738170
   PubMed Web of Science ®Google Scholar
• Varsaldi F, Miglio G, Scordo MG, et al. Impact of the CYP2D6 polymorphism on steady-state plasma concentrations and clinical outcome of donepezil in Alzheimer’s disease patients. Eur J Clin Pharmacol. 2006;62(9):721–726. doi:10.1007/s00228-006-0168-116845507
   PubMed Web of Science ®Google Scholar
• Klimkowicz-Mrowiec A, Wolkow P, Sado M, et al. Influence of rs1080985 single nucleotide polymorphism of the CYP2D6 gene on response to treatment with donepezil in patients with alzheimer’s disease. Neuropsychiatr Dis Treat. 2013;9:1029–1033. doi:10.2147/NDT.S4668923950644
   PubMed Web of Science ®Google Scholar
• Liu M, Zhang Y, Huo YR, et al. Influence of the rs1080985 single nucleotide polymorphism of the CYP2D6 gene and APOE polymorphism on the response to donepezil treatment in patients with Alzheimer’s disease in China. Dement Geriatr Cogn Dis Extra. 2014;4(3):450–456. doi:10.1159/00036759625538729
   PubMedGoogle Scholar
• Suwannasri P, Thongnoppakhun W, Pramyothin P, Assawamakin A, Limwongse C. Combination of multiplex PCR and DHPLC-based strategy for CYP2D6 genotyping scheme in Thais. Clin Biochem. 2011;44(13):1144–1152. doi:10.1016/j.clinbiochem.2011.06.98521763299
   PubMed Web of Science ®Google Scholar
• Liu CC, Liu CC, Kanekiyo T, Xu H, Bu G. Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy. Nat Rev Neurol. 2013;9(2):106–118. doi:10.1038/nrneurol.2012.26323296339
   PubMed Web of Science ®Google Scholar
• Rungsanpanya T, Muangpaisan W, Praditsuwan R. Clinical practice with antidementia drugs in a geriatric clinic. J Med Assoc Thai. 2012;95(8):1081–1089.23061314
   PubMedGoogle Scholar
• Train The Brain Forum Committee TTBFC. Thai mental state examination (TMSE). Siriraj Medical Journal 2017;45(6):16.
   Google Scholar
• Chaudhary R, Likidlilid A, Peerapatdit T, et al. Apolipoprotein E gene polymorphism: effects on plasma lipids and risk of type 2 diabetes and coronary artery disease. Cardiovasc Diabetol. 2012;11:36. doi:10.1186/1475-2840-11-3622520940
   PubMed Web of Science ®Google Scholar
• Ponnayyan Sulochana S, Sharma K, Mullangi R, Sukumaran SK. Review of the validated HPLC and LC-MS/MS methods for determination of drugs used in clinical practice for Alzheimer’s disease. Biomed Chromatogr. 2014;28(11):1431–1490. doi:10.1002/bmc.311624515838
   PubMed Web of Science ®Google Scholar
• Xie Z, Liao Q, Xu X, Yao M, Wan J, Liu D. Rapid and sensitive determination of donepezil in human plasma by liquid chromatography/tandem mass spectrometry: application to a pharmacokinetic study. Rapid Commun Mass Spectrom. 2006;20(21):3193–3198. doi:10.1002/rcm.271817016805
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration. Guidance for Industry: Bioanalytical Method Validation. Rockville, MD : US Department of Health and Human Services, FDA, Center for Drug Evaluation and Research; 2001. 
   Google Scholar
• Koeber R, Kluenemann -H-H, Waimer R, et al. Implementation of a cost-effective HPLC/UV-approach for medical routine quantification of donepezil in human serum. J Chromatogr B. 2012;881–882:1–11. doi:10.1016/j.jchromb.2011.10.027
   PubMed Web of Science ®Google Scholar
• Zhong Y, Zheng X, Miao Y, Yan H, Wang B, Wan L. Effect of CYP2D6*10 and APOE polymorphisms on the efficacy of donepezil in patients with Alzheimer’s disease. Am J Med Sci. 2013;345(3):222–226. doi:10.1097/MAJ.0b013e318255a8f922986607
   PubMed Web of Science ®Google Scholar
• Chamnanphon M, Gaedigk A, Vanwong N, et al. CYP2D6 genotype analysis of a Thai population: platform comparison. Pharmacogenomics. 2018;19(12):947–960. doi:10.2217/pgs-2018-007529992861
   PubMed Web of Science ®Google Scholar
• Ota T, Kamada Y, Hayashida M, Iwao-Koizumi K, Murata S, Kinoshita K. Combination analysis in genetic polymorphisms of drug-metabolizing enzymes CYP1A2, CYP2C9, CYP2C19, CYP2D6 and CYP3A5 in the Japanese population. Int J Med Sci. 2015;12(1):78–82. doi:10.7150/ijms.1026325552922
   PubMed Web of Science ®Google Scholar
• Beverage JN, Sissung TM, Sion AM, Danesi R, Figg WD. CYP2D6 polymorphisms and the impact on tamoxifen therapy. J Pharm Sci. 2007;96(9):2224–2231. doi:10.1002/jps.2089217518364
   PubMed Web of Science ®Google Scholar
• Coin A, Pamio MV, Alexopoulos C, et al. Donepezil plasma concentrations, CYP2D6 and CYP3A4 phenotypes, and cognitive outcome in Alzheimer’s disease. Eur J Clin Pharmacol. 2016;72(6):711–717. doi:10.1007/s00228-016-2033-126952092
   PubMed Web of Science ®Google Scholar
• Nagy CF, Kumar D, Perdomo CA, Wason S, Cullen EI, Pratt RD. Concurrent administration of donepezil HCl and sertraline HCl in healthy volunteers: assessment of pharmacokinetic changes and safety following single and multiple oral doses. Br J Clin Pharmacol. 2004;58(Suppl 1):25–33. doi:10.1111/j.1365-2125.2004.01801.x15496220
   PubMed Web of Science ®Google Scholar
• Micuda S, Mundlova L, Anzenbacherova E, et al. Inhibitory effects of memantine on human cytochrome P450 activities: prediction of in vivo drug interactions. Eur J Clin Pharmacol. 2004;60(8):583–589. doi:10.1007/s00228-004-0825-115378224
   PubMed Web of Science ®Google Scholar
• Peñas-Lledó EM, Llerena A. CYP2D6 variation, behaviour and psychopathology: implications for pharmacogenomics-guided clinical trials. Br J Clin Pharmacol. 2014;77(4):673–683. doi:10.1111/bcp.1222724033670
   PubMed Web of Science ®Google Scholar
• Darreh-Shori T, Meurling L, Pettersson T, et al. Changes in the activity and protein levels of CSF acetylcholinesterases in relation to cognitive function of patients with mild Alzheimer’s disease following chronic donepezil treatment. J Neural Transm (Vienna). 2006;113(11):1791–1801. doi:10.1007/s00702-006-0526-216868793
   PubMed Web of Science ®Google Scholar
• Jellinger KA. Pathology and pathogenesis of vascular cognitive impairment-a critical update. Front Aging Neurosci. 2013;5:17. doi:10.3389/fnagi.2013.0001723596414
   PubMed Web of Science ®Google Scholar
• Kirchheiner J, Seeringer A, Godoy AL, et al. CYP2D6 in the brain: genotype effects on resting brain perfusion. Mol Psychiatry. 2010;16:333. doi:10.1038/mp.2010.42
   Web of Science ®Google Scholar
• Miranda LF, Gomes KB, Tito PA, et al. Clinical response to donepezil in mild and moderate dementia: relationship to drug plasma concentration and CYP2D6 and APOE genetic polymorphisms. J Alzheimers Dis. 2017;55(2):539–549. doi:10.3233/JAD-16016427716659
   PubMed Web of Science ®Google Scholar
• Xiao T, Jiao B, Zhang W, Tang B, Shen L. Effect of the CYP2D6 and APOE polymorphisms on the efficacy of donepezil in patients with Alzheimer’s disease: a systematic review and meta-analysis. CNS Drugs. 2016;30(10):899–907. doi:10.1007/s40263-016-0356-127282366
   PubMed Web of Science ®Google Scholar
• Noetzli M, Guidi M, Ebbing K, et al. Population pharmacokinetic approach to evaluate the effect of CYP2D6, CYP3A, ABCB1, POR and NR1I2 genotypes on donepezil clearance. Br J Clin Pharmacol. 2014;78(1):135–144. doi:10.1111/bcp.1232524433464
   PubMed Web of Science ®Google Scholar
• Mokhber N, Abdollahian E, Soltanifar A, et al. Comparison of sertraline, venlafaxine and desipramine effects on depression, cognition and the daily living activities in Alzheimer patients.Pharmacopsychiatry. 2014;47:131–140.
   Google Scholar
• Wattmo C, Wallin ÅK, Minthon L. Functional response to cholinesterase inhibitor therapy in a naturalistic Alzheimer’s disease cohort. BMC Neurol. 2012;12(1):134. doi:10.1186/1471-2377-12-13423126532
   PubMed Web of Science ®Google Scholar
• Pasqualetti G, Tognini S, Calsolaro V, Polini A, Monzani F. Potential drug-drug interactions in Alzheimer patients with behavioral symptoms. Clin Interv Aging. 2015;10:1457–1466. doi:10.2147/CIA.S8746626392756
   PubMed Web of Science ®Google Scholar
• Ye CY, Lei Y, Tang XC, Zhang HY. Donepezil attenuates Abeta-associated mitochondrial dysfunction and reduces mitochondrial Abeta accumulation in vivo and in vitro. Neuropharmacology. 2015;95:29–36. doi:10.1016/j.neuropharm.2015.02.02025744714
   PubMed Web of Science ®Google Scholar
• Hu P, Qin YH, Jing CX, Lu L, Hu B, Du PF. Does the geographical gradient of ApoE4 allele exist in China? A systemic comparison among multiple Chinese populations. Mol Biol Rep. 2011;38(1):489–494. doi:10.1007/s11033-010-0132-020354905
   PubMed Web of Science ®Google Scholar
• Kobayashi S, Tateno M, Park TW, et al. Apolipoprotein E4 frequencies in a Japanese population with Alzheimer’s disease and dementia with Lewy bodies. PLoS One. 2011;6(4):e18569–e18569. doi:10.1371/journal.pone.001856921552550
   PubMed Web of Science ®Google Scholar